Executive Summary
- Cardiovascular Imaging: Trends and Implications
- In Vitro Cardiovascular Diagnostics: Trends and Implications
Chapter 1. Background Trends in Cardiovascular Disease
- 1.1 Cardiovascular Disease Statistics
- Coronary Heart Disease
- Congestive Heart Failure
- Hypertension
- Stroke
- Cardiac Arrhythmias
- Other Cardiovascular Disease
- 1.2 Prospects for Cardio-Theranostics
Chapter 2. Cardiovascular Imaging
- 2.1 Ultrasound
- Competition
- Market Trends and Developments
- 2.2 Magnetic Resonance
- Competition
- Market Trends and Developments
- 2.3 Computed Tomography
- Competition
- Market Trends
- 2.4 Nuclear Medicine
- SPECT Imaging
- -Competition and Market Trends
- PET Imaging
- -Competition and Market Trends
Chapter 3. Biomarkers for Cardiovascular Diagnostics
- 3.1 Biomarkers for Determining Risk in Coronary Artery Disease (CAD)
- Description of Biomarkers for Risk of CAD
- -C-Reactive Protein
- -Lp-PLA2
- -Homocysteine
- -LDL Subclasses and Particle Size
- -Lipoprotein (a)
- -Apolipoprotein A and Apolipoprotein B
- Medical and Economic Impact
- Competition and Outlook
- 3.2 Biomarkers For Diagnosis of Acute Coronary Syndrome
- Description of Current Markers for Acute Coronary Syndrome
- -Creatine Kinase MB Isoenzymes (CK-MB)
- -Troponin I and Troponin T
- -Myoglobin
- -Heart Fatty Acid Binding Proteins
- -Ischemia-Modified Albumin
- Potential Future Biomarkers for Acute Coronary Syndrome
- -Blood Choline
- -CD40 Ligand
- -Chemoattractant Biomarkers
- -Glutathione Peroxidase 1
- -Myeloperoxidase
- -Pregnancy-Associated Plasma Protein-A
- -Serum Deoxyribonuclease I Activity
- -Unbound Free-Fatty Acids
- Medical and Economic Impact
- Competition and Outlook
- Biomarkers for Congestive Heart Failure
- -Medical and Economic Impact
- -Competition and Outlook
- 3.4 Thrombosis Markers
- Description of Biomarkers and Genetic Markers
- -D-Dimer
- -Factor V Leiden
- -Prothrombin Factor II (PT 20210A)
- -Methylene-tetra-hydro-folate-reductase (MTHFR) Gene
- -Plaminogen Activator Inhibitor-1
- Medical and Economic Impact
- Competition and Outlook
- 3.5 Potential Future Markers for Stroke
- Description of Potential Stroke Markers
- -Neuron-Specific Enolase
- -S-100B
- -Matrix Metalloproteinases
- -Stroke Panel
- Medical and Economic Impact
- Competition and Outlook
- 3.6 Cardio-Theranostics
- Pharmacogenetics
- -Cytochrome P450
- -CYP2D6
- -CYP2C9
- -Cholesterol Ester Transfer Protein
- -Angiotensin-Converting Enzyme Gene
- -Beta-1 and Beta-2 Adrenergic Receptor Gene
- -N-Acetyltransferase-2 Gene
- -Platelet Fc-Gamma-Receptor Gene
- -Alpha-Adducin Gene Variant
- -Apolipoprotein E Genotyping
- Other Cardio-Theranostics
- -Antiplatelet Drug Testing
- -Aspirin Resistance Test
- Medical and Economic Impact
- Competition and Outlook
Chapter 4. Expert Interviews
- Cardiovascular In Vitro Diagnostic Interviews
- -Alberto Abate, bioMérieux
- -Kenneth F. Buechler, PhD, Biosite
- -Hans-Juergen Loyda, Roche Diagnostics
- -David Ludvigson, Nanogen, Inc.
- --Biomarker Tests
- --Genomic Testing
- -- New Biomarkers
- Cardiovascular Imaging Interviews
- -James Kronauge, PhD, Molecular Insight
- -Gregg Mayer, EPIX Pharmaceuticals
Chapter 5. Company Profiles
- Abaxis
- Abbott Diagnostics
- Atherotech
- Bayer HealthCare
- Beckman Coulter
- Berlex Laboratories, Inc.
- bioMérieux SA
- Biosite
- Bracco Diagnostics
- Bristol Myers Squibb Medical Imaging
- Cholestech
- Dade Behring
- Diagnostic Products Corp. (DPC)
- GE Healthcare
- Instrumentation Laboratory
- International Technidyne Corp (ITC)
- Ischemia Technologies
- LipoScience
- Mallinkrodt
- Nanogen
- Ortho Clinical Diagnostics
- Philips Medical Systems
- Response Biomedical
- Roche Diagnostics
- Siemens Medical Solutions
- Spectral Diagnostics
- Sysmex
- Third Wave Technology
- References
- Index
|
Related Report
|
View Cart
